PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference

BOSTON, Feb. 28 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the Raymond James 29th Annual Institutional Investors Conference at the Hyatt Regency Grand Cypress in Orlando, Florida. James Winschel, Senior Vice President and Chief Financial Officer will be making a formal presentation on PAREXEL at 4:00 p.m. ET on Monday, March 3, 2008.

A live webcast of this presentation will be available through the "Investor Relations Webcasts" section of PAREXEL's web site at http://www.PAREXEL.com and a replay of the presentation will be available until April 3, 2008.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has over 7,050 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

SOURCE PAREXEL International Corporation

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.